Clinical Trial

Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation

Study acronym: HALT
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To verify whether albumin administration to achieve serum concentration above 30g/L (treated group) and its maintenance within plasmatic physiologic range (above 30 g/L) for five days diminishes rate of AKI at Day 7 after liver transplantation as compared to restrained albumin administration (when serum concentration is at 20 g/L or below (control)).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-07-30; most recent amendment 2026-06-16.
Status change: Not Yet Recruiting → Recruiting 2025-03-26
Trial Details
NCT Number NCT06535945
Lead Sponsor Rennes University Hospital
Collaborators: Ministry of Health, France
Conditions Liver Transplantation, Acute Kidney Injury
Enrollment 400 participants
Start Date 2025-03-26
Primary Completion 2028-04-26 (estimated)
Study Completion 2028-04-26 (estimated)
Updated on ClinicalTrials.gov 2026-06-17